Guaiac faecal occult blood test performance at initial and repeat screens in the English Bowel Cancer Screening Programme

British Journal of Cancer

Volumn 111, Issue 9, 2014, Pages 1734-1741

  Kearns, B ^a   Whyte, S ^a   Chilcott, J ^a   Patnick, J ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

bowel cancer; colorectal cancer screening; cost effectiveness; sensitivity; specificity

Indexed keywords

GUAIAC;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SCREENING; COLORECTAL CANCER; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ECONOMIC EVALUATION; FOLLOW UP; GUAIAC FECAL OCCULT BLOOD TEST; HIGH RISK POPULATION; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; OCCULT BLOOD TEST; PREDICTIVE VALUE; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; SOCIAL WORK; UNITED KINGDOM; ADENOMA; COLONOSCOPY; COLORECTAL NEOPLASMS; DIAGNOSTIC USE; EARLY DIAGNOSIS; FEMALE; MALE; MIDDLE AGED; OCCULT BLOOD; PROCEDURES; PROGNOSIS;

ADENOMA; AGED; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; GUAIAC; HUMANS; MALE; MIDDLE AGED; OCCULT BLOOD; PROGNOSIS;

EID: 84908505502     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.469     Document Type: Article

References (32)

1. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, Parkin DM, Wardle J, Duffy SW, Cuzick J (2010) Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: A multicentre randomised controlled trial. Lancet 375(9726): 1624-1633.
2. Benson VS, Atkin WS, Green J, Nadel MR, Patnick J, Smith RA, Villain P (2012) Toward standardizing and reporting colorectal cancer screening indicators on an international level: The International Colorectal Cancer Screening Network. Int J Cancer 130(12): 2961-2973.
3. Berchi C, Bouvier V, Reaud JM, Launoy G (2004) Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France. Health Econ 13(3): 227-238.
4. Burch JA, Soares-Weiser St K, John DJB, Duffy S, Smith S, Kleijnen J, Westwood M (2007) Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: A systematic review. J Med Screen 14(3): 132-137.
5. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, Eaden JA, Rutter MD, Atkin WP, Saunders BP (2010) Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 59(5): 666-689.
6. Cancer Research UK (2013) Cancer Statistics: Key Facts: Bowel Cancer April 2013. http://publications.cancerresearchuk.org/downloads/Product/CS-KF-BOWEL.pdf.
7. Castiglione G, Grazzini G, Miccinesi G, Rubeca T, Sani C, Turco P, Zappa M (2002) Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood. J Med Screen 9(3): 99-103.
8. Day NE (1985) Estimating the sensitivity of a screening test. J Epidemiol Community Health 39(4): 364-366.
9. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM (2000) Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 284(15): 1954-1961.
10. Heitman SJ, Hilsden RJ, Au F, Dowden S, Manns BJ (2010) Colorectal cancer screening for average-risk North Americans: An economic evaluation. PLoS Med 7(11): E1000370.
11. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L (2008) Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): An update. Am J Gastroenterol 103(6): 1541-1549.
12. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME (2004) Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 351(26): 2704-2714.
13. Janda M, Hughes KL, Auster JF, Leggett BA, Newman BM (2010) Repeat participation in colorectal cancer screening utilizing fecal occult blood testing: A community-based project in a rural setting. J Gastroenterol Hepatol 25(10): 1661-1667.
14. Kraemer HC (1985) The robustness of common measures of 2-2 association to bias due to misclassifications. Am Stat 39(4): 286-290.
15. Lansdorp-Vogelaar I, Knudsen AB, Brenner H (2011) Cost-effectiveness of colorectal cancer screening. Epidemiol Rev 33(1): 88-100.
16. Leeflang MM, Bossuyt PM, Irwig L (2009) Diagnostic test accuracy may vary with prevalence: Implications for evidence-based diagnosis. J Clin Epidemiol 62(1): 5-12.
17. Logan RF, Patnick J, Nickerson C, Coleman L, Rutter MD, von Wagner C (2012) Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. Gut 61(10): 1439-1446.
18. Macafee DAL, Waller M, Whynes DK, Moss S, Scholefield JH (2008) Population screening for colorectal cancer: The implications of an ageing population. Br J Cancer 99(12): 1991-2000.
19. Moss SM, Hardcastle JD, Coleman DA, Robinson MH, Rodrigues VC (1999) Interval cancers in a randomized controlled trial of screening for colorectal cancer using a faecal occult blood test. Int J Epidemiol 28(3): 386-390.
20. National Cancer Intelligence Network (2013) Colorectal cancer survival by stage. http://www.ncin.org.uk/publications/data-briefings/colorectal-cancer-survival-by-stage.
21. National Institute for Health and Care Excellence (2013) Guide to the methods of technology appraisal. http://publications.nice.org.uk/guide-To-Themethods-of-Technology-Appraisal-2013-pmg9.
22. Newcombe RG (2012) Confidence intervals for proportions and related measures of effect size. CRC Press: Boca Raton, FL, USA.
23. O'Leary BA, Olynyk JK, Neville A, Platell CF (2004) Cost-effectiveness of colorectal cancer screening: Comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy. J Gastroenterol Hepatol 19(1): 38-47.
24. Song K, Fendrick AM, Ladabaum U (2004) Fecal DNA testing compared with conventional colorectal cancer screening methods: A decision analysis. Gastroenterology 126(5): 1270-1279.
25. Steele RJC, Kostourou I, McClements P, Watling C, Libby G, Weller D, Brewster DH, Black R, Carey FA, Fraser C (2010) Effect of repeated invitations on uptake of colorectal cancer screening using faecal occult blood testing: Analysis of prevalence and incidence screening. BMJ 341: C5531.
26. Steele RJ, McClements PL, Libby G, Black R, Morton C, Birrell J, Mowat NAG, Wilson JA, Kenicer M, Carey FA (2009) Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer. Gut 58(4): 530-535.
27. Tsoi KKF, Ng SSM, Leung MCM, Sung JJY (2008) Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia. Aliment Pharmacol Ther 28(3): 353-363.
28. Whyte S, Chilcott J, Essat M, Stevens J, Wong R, Kalita N (2011a) Reappraisal of the options for colorectal cancer screening. Report for the NHS Bowel Cancer Screening Programme. http://www.screening.nhs.uk/policydb-download.php?doc=130.
29. Whyte S, Chilcott J, Halloran S (2012) Reappraisal of the options for colorectal cancer screening in England. Colorectal Disease 14(9): E547-e561.
30. Whyte S, Walsh C, Chilcott J (2011b) Bayesian calibration of a natural history model with application to a population model for colorectal cancer. Med Decis Making 31(4): 625-641.
31. Wu GH, Wang YM, Yen AM, Wong JM, Lai HC, Warwick J, Chen TH (2006) Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries. BMC Cancer 6(1): 136.
32. Zappa M, Castiglione G, Paci E, Grazzini G, Rubeca T, Turco P, Crocetti E, Ciatto S (2001) Measuring interval cancers in population-based screening using different assays of fecal occult blood testing: The district of Florence experience. Int J Cancer 92(1): 151-154.